Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- THTX
- Price
- 2.52
- Stock movement down
- -0.05 (-1.95%)
- Company name
- Theratechnologies Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 115.87M
- Ent value
- 170.57M
- Price/Sales
- 1.28
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 26.25
- Forward P/E
- 12.17
- PEG
- -
- EPS growth
- 29.73%
- 1 year return
- 96.88%
- 3 year return
- -36.92%
- 5 year return
- -20.86%
- 10 year return
- -1.60%
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
THTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 26.25 |
| Price to OCF | 24.98 |
| Price to FCF | 60.64 |
| Price to EBITDA | 8.03 |
| EV to EBITDA | 11.82 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.28 |
| Price to Book | - |
| EV to Sales | 1.88 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 45.98M |
| EPS (TTM) | 0.09 |
| FCF per share (TTM) | 0.04 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 90.66M |
| Gross profit (TTM) | 71.65M |
| Operating income (TTM) | 19.43M |
| Net income (TTM) | 4.41M |
| EPS (TTM) | 0.09 |
| EPS (1y forward) | 0.21 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 79.03% |
| Operating margin (TTM) | 21.44% |
| Profit margin (TTM) | 4.87% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.69M |
| Net receivables | 10.31M |
| Total current assets | 57.25M |
| Goodwill | 0.00 |
| Intangible assets | 11.42M |
| Property, plant and equipment | 788.00K |
| Total assets | 69.71M |
| Accounts payable | 23.76M |
| Short/Current long term debt | 57.83M |
| Total current liabilities | 52.90M |
| Total liabilities | 89.39M |
| Shareholder's equity | -19.68M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 4.64M |
| Capital expenditures (TTM) | 2.99M |
| Free cash flow (TTM) | 1.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | 6.33% |
| Return on Invested Capital | 11.64% |
| Cash Return on Invested Capital | 5.04% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.60 |
| Daily high | 2.67 |
| Daily low | 2.51 |
| Daily Volume | 758K |
| All-time high | 51.81 |
| 1y analyst estimate | 3.77 |
| Beta | 1.73 |
| EPS (TTM) | 0.09 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 8 Jul 2025 |
Downside potential
Loading...
Downside potential data
| THTX | S&P500 | |
| Current price drop from All-time high | -95.14% | -14.12% |
| Highest price drop | -98.60% | -56.47% |
| Date of highest drop | 25 Sep 2013 | 9 Mar 2009 |
| Avg drop from high | -75.28% | -11.07% |
| Avg time to new high | 257 days | 12 days |
| Max time to new high | 4304 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
115.87M
Marketcap category
Small-cap
Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Employees
103
Website
Investor relations
-
SEC filings
CEO
Luc Tanguay
Country
USA
City
Montréal
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page